Daiichi Sankyo secures $47M in ADC Patent arbitration against Seagen, faces upcoming conflict with Pfizer

CAR-T Digest - August 2020

01 July 2024: Daiichi Sankyo secures $47M in ADC Patent arbitration against Seagen, faces upcoming conflict with Pfizer

Daiichi Sankyo has emerged victorious in a longstanding patent arbitration dispute against Seagen, securing payment of $47 million in attorneys’ fees and costs, plus interest
The dispute centered around technologies related to Daiichi Sankyo’s Enhertu, an antibody-drug conjugate (ADC) developed in partnership with AstraZeneca
An arbitrator initially ruled in favor of Daiichi Sankyo in August 2022, deeming Seagen’s claims invalid
Despite Seagen’s efforts to challenge and vacate the ruling, a federal court upheld the arbitrator’s decision in April 2024, solidifying Daiichi Sankyo’s victory
The broader patent battle involving Pfizer’s acquisition of Seagen for $43 billion in 2023 continues, despite this specific legal setback for Seagen